Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 4/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819927 | 0.83 | ALDH1A1 (0.46) | PIM1KDM4EKMT2AMMP2CA1 | |
| SCHEMBL4823327 | 0.82 | PIM1 (0.69) | PIM1KDM4EKMT2APARP1HTR3A | |
| Carbamic Acid SCHEMBL2670938 | 0.79 | KDM4E (0.62) | PIM1KDM4EKMT2AMMP2 | |
| SCHEMBL3388245 | 0.78 | KDM4E (0.66) | PIM1KDM4EKMT2AMMP2 | |
| SCHEMBL29831204 | 0.78 | KDM4E (0.66) | PIM1KDM4EKMT2AMMP2 | |
| SCHEMBL8541555 | 0.76 | ALDH1A1 (0.54) | PIM1KDM4EKMT2APLAUCYP1A2 | |
| SCHEMBL10635595 | 0.76 | MGAM (0.58) | KDM4EKMT2A | |
| SCHEMBL5202897 | 0.76 | MTNR1A (0.42) | PIM1KDM4EKMT2APARP1HTR3A | |
| SCHEMBL28346452 | 0.73 | PIM1 (0.45) | PIM1KDM4EKMT2APARP1HTR3A | |
| SCHEMBL27998643 | 0.73 | CNR2 (0.58) | PIM1KDM4EKMT2AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108529-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| WO-2010132852-A2 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108529-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | PIM1 390/4885KDM4E 858/4885KMT2A 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.